Novel Compounds - Inflazome Limited EP3759102A1

The EPO published patent application EP3759102A1 for Inflazome Limited covering novel heterocyclic compounds (C07D) for pharmaceutical use (A61K). The patent designates all EU member states and several additional European countries including the UK, Switzerland, and Norway. IPC classifications indicate applications in anti-inflammatory therapeutics (A61P 29/00).

Competitors developing similar heterocyclic compounds for inflammatory conditions should review the patent claims to assess potential freedom-to-operate concerns. The designated state coverage means patent protection may be sought across the full EU territory upon national phase entry.